Athersys to Present at the Bank of America Virtual Healthcare Conference on May 12

Ivor Macleod, CFO of Athersys (NASDAQ: ATHX), will present at the Bank of America Securities 2021 Virtual Health Care Conference on May 12, 2021, at 12:30 PM EDT.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

04/28/2021 - 01:00 PM EDT

Ivor Macleod, Chief Financial Officer of Athersys Inc. (NASDAQ: ATHX), is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 12:30 pm EDT. Following a brief corporate update, Mr. Macleod will engage in a Q & A fireside chat with a Bank of America analyst. The Company will also engage in virtual meetings with other institutional representatives at the conference.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.athersys.com. An archived replay of the webcast will be available 24 hours after the conclusion of the live event on the Company's website after the conference for a limited time.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem^® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.